Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey R Oxnard

Showing results (91-100 of 199) with videos related to

Pageof 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2018
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung AdenocarcinomasSusan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, et al.
JTO Clinical and Research Reports|September 12, 2022
Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLCLee S Schwartzberg, Gerald Li, Khaled Tolba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2011
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assayMaria E Arcila, Geoffrey R Oxnard, Khedoudja Nafa, et al.
Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotypingNicolas Guibert, Hisashi Tsukada, David H Hwang, et al.
NPJ Precision Oncology|January 23, 2023
Genomic landscape of 891 RET fusions detected across diverse solid tumor typesVamsi Parimi, Khaled Tolba, Natalie Danziger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2020
Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung AdenocarcinomasSusan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2019
Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomasJacob M Sands, Tom Nguyen, Priyanka Shivdasani, et al.
JCO Precision Oncology|July 12, 2021
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLCMichael L Cheng, Christie J Lau, Marina S D Milan, et al.
JCO Precision Oncology|June 7, 2024
Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic MelanomaMiles C Andrews, Gerald Li, Ryon P Graf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2015
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung AdenocarcinomaAntonio Calles, Lynette M Sholl, Scott J Rodig, et al.
Pageof 20

Showing results (91-100 of 199) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2018
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung AdenocarcinomasSusan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, et al.
JTO Clinical and Research Reports|September 12, 2022
Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLCLee S Schwartzberg, Gerald Li, Khaled Tolba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2011
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assayMaria E Arcila, Geoffrey R Oxnard, Khedoudja Nafa, et al.
Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotypingNicolas Guibert, Hisashi Tsukada, David H Hwang, et al.
NPJ Precision Oncology|January 23, 2023
Genomic landscape of 891 RET fusions detected across diverse solid tumor typesVamsi Parimi, Khaled Tolba, Natalie Danziger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2020
Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung AdenocarcinomasSusan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2019
Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomasJacob M Sands, Tom Nguyen, Priyanka Shivdasani, et al.
JCO Precision Oncology|July 12, 2021
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLCMichael L Cheng, Christie J Lau, Marina S D Milan, et al.
JCO Precision Oncology|June 7, 2024
Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic MelanomaMiles C Andrews, Gerald Li, Ryon P Graf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2015
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung AdenocarcinomaAntonio Calles, Lynette M Sholl, Scott J Rodig, et al.
Pageof 20